Technical Analysis for IMGN - ImmunoGen, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
20 DMA Resistance | Bearish | 3.90% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.90% | |
Stochastic Buy Signal | Bullish | 6.88% | |
Lower Bollinger Band Walk | Weakness | 6.88% | |
Gapped Up | Strength | 6.88% | |
Oversold Stochastic | Weakness | 6.88% | |
NR7 | Range Contraction | 9.36% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 1 ATR | about 10 hours ago |
Up 3% | about 11 hours ago |
10 DMA Support | about 12 hours ago |
Up 2% | about 12 hours ago |
Up 1% | about 13 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/02/2023
ImmunoGen, Inc. Description
ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Solid Tumors Drugs Monoclonal Antibodies Breast Cancer Lymphoma Non Small Cell Lung Cancer Ovarian Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Medical Research Multiple Myeloma Antibody Drug Conjugate Her2 Chronic Lymphocytic Leukemia Hematological Malignancies Lymphocytic Leukemia Clinical Trial Product Cancer Therapeutics Acute Lymphoblastic Leukemia Immunogen Metastatic Breast Cancer B Cell Acute Lymphoblastic Leukemia Mesothelin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 20.69 |
52 Week Low | 3.61 |
Average Volume | 4,192,736 |
200-Day Moving Average | 10.48 |
50-Day Moving Average | 16.08 |
20-Day Moving Average | 15.46 |
10-Day Moving Average | 15.24 |
Average True Range | 0.62 |
RSI (14) | 54.95 |
ADX | 19.33 |
+DI | 25.82 |
-DI | 25.47 |
Chandelier Exit (Long, 3 ATRs) | 14.57 |
Chandelier Exit (Short, 3 ATRs) | 16.27 |
Upper Bollinger Bands | 16.31 |
Lower Bollinger Band | 14.61 |
Percent B (%b) | 0.82 |
BandWidth | 10.94 |
MACD Line | -0.22 |
MACD Signal Line | -0.28 |
MACD Histogram | 0.0604 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 17.23 | ||||
Resistance 3 (R3) | 17.10 | 16.57 | 17.03 | ||
Resistance 2 (R2) | 16.57 | 16.25 | 16.63 | 16.96 | |
Resistance 1 (R1) | 16.28 | 16.06 | 16.43 | 16.41 | 16.89 |
Pivot Point | 15.75 | 15.75 | 15.82 | 15.81 | 15.75 |
Support 1 (S1) | 15.46 | 15.43 | 15.61 | 15.59 | 15.11 |
Support 2 (S2) | 14.93 | 15.24 | 14.99 | 15.04 | |
Support 3 (S3) | 14.64 | 14.93 | 14.98 | ||
Support 4 (S4) | 14.77 |